FUSN Stock Overview
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Fusion Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.24 |
| 52 Week High | US$21.55 |
| 52 Week Low | US$2.31 |
| Beta | -0.72 |
| 1 Month Change | 99.62% |
| 3 Month Change | 137.58% |
| 1 Year Change | 457.48% |
| 3 Year Change | 143.02% |
| 5 Year Change | n/a |
| Change since IPO | 24.94% |
Recent News & Updates
Recent updates
Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook
Mar 03Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?
Jan 30
Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors
Sep 16Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment
Aug 29Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?
Aug 10Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M
Aug 09Fusion Pharma wins FDA nod to start trials for solid tumor candidate
Jun 23We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Jan 16We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Aug 28Fusion Pharma trades higher on early-stage data for cancer therapy
Jun 14We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely
Apr 05How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?
Mar 01Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?
Jan 25Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation
Dec 21Fusion Pharmaceuticals EPS misses by $0.04
Nov 10Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
Nov 02Shareholder Returns
| FUSN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | -4.2% | -3.7% |
| 1Y | 457.5% | -2.0% | 20.5% |
Return vs Industry: FUSN exceeded the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: FUSN exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| FUSN volatility | |
|---|---|
| FUSN Average Weekly Movement | 29.3% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FUSN's share price has been volatile over the past 3 months.
Volatility Over Time: FUSN's weekly volatility has increased from 18% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 101 | John Valliant | www.fusionpharma.com |
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company’s lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations.
Fusion Pharmaceuticals Inc. Fundamentals Summary
| FUSN fundamental statistics | |
|---|---|
| Market cap | US$1.80b |
| Earnings (TTM) | -US$94.90m |
| Revenue (TTM) | US$2.07m |
869.9x
P/S Ratio-19.0x
P/E RatioIs FUSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FUSN income statement (TTM) | |
|---|---|
| Revenue | US$2.07m |
| Cost of Revenue | US$70.10m |
| Gross Profit | -US$68.03m |
| Other Expenses | US$26.86m |
| Earnings | -US$94.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.12 |
| Gross Margin | -3,289.89% |
| Net Profit Margin | -4,588.83% |
| Debt/Equity Ratio | 15.6% |
How did FUSN perform over the long term?
See historical performance and comparison